AMNOG assessment report misses key factors for industry
This article was originally published in Scrip
A government report on Germany's tough AMNOG pricing and reimbursement system has failed to address key problems with the system, according to Matthias Heck, Brussels representative for the BPI, a German pharmaceutical industry association.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.